Elora

Quick links to important sections

Elora

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elora

Quick Facts

Property Description
Active Ingredient Desloratadine (INN)
Form Tablet, Orally Disintegrating Tablet (ODT), Oral Solution
Pharmacological Class Second-generation Antihistamine
General Purpose Relief from allergic conditions
Origin Synthetic (Active Metabolite)

What Type of Medicine is Elora?

Elora is a medicinal product containing the active ingredient Desloratadine, which is classified as a modern, second-generation antihistamine and a potent Histamine H1-receptor antagonist. The drug's fundamental function is to provide continuous anti-allergic action against symptoms stemming from common allergic conditions. Pharmacological studies have clinically recognized Desloratadine for its sustained efficacy in providing relief from general allergic discomfort.

This medication belongs to the tricyclic antihistamine sub-group and is defined by its selective action. Its chemical properties limit its ability to penetrate the blood-brain barrier, making it generally non-sedating for most individuals, which is a key differentiating factor from older treatments.


Desloratadine: Composition and Origin

The core of Elora’s efficacy is Desloratadine, which is synthetically derived and acts as the major active metabolite of the precursor compound Loratadine. This structure means the compound is readily available for action upon absorption, providing a potent and predictable therapeutic effect.

Desloratadine is supplied for oral administration in several dosage form(s), including the film-coated tablet, the fast-dissolving orally disintegrating tablet (ODT), and a liquid oral solution (syrup), each consisting of the active compound combined with an appropriate pharmaceutical base or vehicle. The liquid form makes this formulation particularly versatile for patient groups, such as younger children, who may have difficulty swallowing tablets.


General Purpose: Targeted Anti-Allergic Action

The general benefit of Elora is rooted in its role as a selective peripheral H1-antagonist, which is the mechanism used to interrupt the body's allergic response. By competing with and blocking the binding of the natural substance Histamine to its receptors, the medicine prevents the initiation of the inflammatory reactions that cause symptoms. This targeted intervention provides systemic, sustained relief from the generalized discomfort associated with allergic conditions.

What side effects are possible with Elora?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics for Desloratadine (Elora), strictly based on government regulatory product labeling (such as the EMA and NIH DailyMed).

Officially Documented Adverse Reactions

Adverse effects are categorized by the frequency of their occurrence and the body's System-Organ Class (SOC) affected:

Frequency Common Adverse Reactions (Adults/Adolescents) System-Organ Class (SOC) Very Rare Adverse Reactions
Common Headache, Fatigue, Dry mouth Cardiac Disorders Tachycardia, Palpitations
Hepatobiliary Disorders Liver enzyme elevations, Hepatitis, Jaundice
Nervous System Disorders Seizures, Dizziness, Somnolence, Insomnia
Not Known QT prolongation, Abnormal behaviour, Aggression, Weight increased Immune System Hypersensitivity reactions, Anaphylaxis, Angioedema

Serious Adverse Reactions and Safety Constraints

Certain reactions, although rare or with a frequency Not Known (meaning they cannot be estimated from available data), are documented due to their severity. These include life-threatening reactions such as Anaphylaxis and severe effects like QT prolongation and Hepatitis.

Population-Specific Safety Considerations:

  • Pediatric Population: Adverse reactions reported in infants (6 to 23 months) included Diarrhea, Fever, and Insomnia.
  • Hepatic or Renal Impairment: Desloratadine should be used with caution in patients with severe renal insufficiency or severe hepatic impairment.
  • Seizure History: Caution is advised in patients with a personal or family history of seizures.

Administration-Agnostic Safety Notes

Regulatory labeling notes that patients should be advised to avoid activities requiring mental alertness, such as operating complex machinery, until they have established their individual response to the product, due to the potential for somnolence (drowsiness).

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived exclusively from governmental regulatory documents describing the overdose profile and emergency actions for Desloratadine (Elora).


Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations The adverse event profile associated with overdose is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher
Physiological systems affected (as stated in label) Post-marketing reports mention seizures (neurological) and QT prolongation, arrhythmia, and bradycardia (cardiac).
Dose-related or exposure-related factors (if applicable) No clinically relevant effects were observed in trials when subjects were exposed to doses up to 45 mg.
Population-specific overdose notes (if applicable) The adverse event profile in the paediatric population associated with overdosage is similar in profile, but the magnitude of the effects can be higher.
Emergency-response statements (as written in official documents) Symptomatic and supportive treatment is recommended. Standard measures to remove unabsorbed active substance should be considered.
When immediate medical help is required (label-derived phrasing only) Call your doctor or get medical attention right away if too much is taken.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity classification (as defined in official documents) Overdose may lead to events with a higher magnitude than therapeutic effects, including severe post-marketing reports.
Regulatory basis (EMA / FDA / etc.) Information is derived from authoritative Summary of Product Characteristics (SmPC) and FDA Prescribing Information.
Overdose-context constraints (as defined in official documents) Desloratadine is not eliminated by haemodialysis; elimination by peritoneal dialysis is not known.

Connection to the Overall Overdose Profile

Regulatory documents establish that while overdose effects are typically similar to known adverse events, the potential for increased severity and specific serious outcomes like neurological or cardiac events mandates that individuals must seek medical attention right away upon suspected overdose. Furthermore, official guidance directs treatment toward symptomatic and supportive care, as mechanical elimination procedures like haemodialysis are noted to be ineffective.

Therapeutic Uses of Elora

What Elora Treats: Main Uses and Benefits

Elora (Desloratadine) may contribute to systemic symptomatic relief for conditions generally driven by allergic immune responses, and may support patients in coping with disruptive and persistent symptoms. The medication is commonly used across therapeutic domains where additional symptomatic support is needed.

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is commonly used to help with conditions such as allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria (hives).

Symptomatic Domains

This therapeutic support may assist with the cluster of symptoms that create noticeable physiological strain, primarily by helping to address sneezing, runny nose, nasal itching, and watery, red eyes associated with respiratory allergies. For skin manifestations, it is commonly used to help with the often disruptive symptoms of generalized pruritus (intense itching) and the appearance of hives (wheals). When applied in addressing these distressing manifestations, the medication may assist with maintaining functional stability and contribute to easing the overall symptom load when symptoms interfere with routine activities and general well-being.


Quick Fact: Supportive Management for Dermal and Respiratory Distress

Domain Focus Primary Symptoms Eased Context of Use
Dermal System Pruritus (itching), Hives/Wheals Recurrent or chronic skin reactions
Respiratory System Sneezing, Rhinorrhea (runny nose) Seasonal or year-round allergen exposure

Regulatory References

  1. National Institutes of Health (NIH) DailyMed product labeling

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Alosetron Hydrochloride

Alosetron Hydrochloride is approved for use only in women who have severe diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and have not responded adequately to conventional therapy. The official regulatory documents impose strict limitations on who can initiate and continue treatment.


Contraindicated Populations and Conditions

The medicine must not be used (is contraindicated) in patients with a history of numerous specific gastrointestinal and vascular disorders, as these conditions are associated with increased risk of serious complications. These prohibitions include:

  • Current or Chronic Constipation: Including a history of complications such as impaction or perforation.
  • Severe Bowel Disorders: Such as intestinal obstruction, ischemic colitis, Crohn’s disease, ulcerative colitis, or diverticulitis.
  • Circulatory/Clotting Conditions: Such as impaired intestinal circulation or a hypercoagulable state.
  • Severe Hepatic Impairment.
  • Concomitant Use of Fluvoxamine.

Age and Gender Restrictions

Use is not established in pediatric patients (children and adolescents). The drug is not recommended for men, as clinical benefits have not been confirmed in this population, nor is it recommended for patients with mild to moderate hepatic impairment, where caution is required. Elderly patients (aged 65 and older) must also be treated with caution due to the increased risk of complications from constipation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Elora (estradiol transdermal system) is primarily defined by its metabolism through the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Interacting Drug Categories and Specific Products

Interaction Mechanism Product Categories Specific Examples (Official Documents)
Decreased Estrogen Levels CYP3A4 Enzyme Inducers Phenytoin, Rifampin, Carbamazepine, Phenobarbital, Dexamethasone, and St. John’s Wort preparations.
Increased Estrogen Levels CYP3A4 Enzyme Inhibitors Ketoconazole, Erythromycin, Clarithromycin, Itraconazole, Ritonavir, and Grapefruit Juice.
Other Interactions Anti-estrogens, Antifibrinolytics Aromatase inhibitors (e.g., Anastrozole), Raloxifene, Tamoxifen, Fezolinetant, Tranexamic Acid.

Interaction Implications

Coadministration with CYP3A4 inducers may accelerate the breakdown of the estradiol patch, which can reduce estrogen plasma concentrations. This reduction may lead to a decrease in the medication's intended therapeutic effects or cause changes in the uterine bleeding profile. Conversely, coadministration with CYP3A4 inhibitors may slow estradiol metabolism, potentially increasing plasma concentrations and resulting in an elevated risk of adverse effects.

Specific pharmacodynamic or clinical interactions are documented with anti-estrogen products like aromatase inhibitors and SERMs, which are not intended for use with estrogen therapy. Additionally, this medication may interfere with the results of certain laboratory tests, requiring healthcare providers and laboratory personnel to be notified.

Mechanism of Action

Direct Blockade of Peripheral H1-Receptors

The primary mechanism involves selective antagonism and inverse agonism at the Histamine H1-receptor. Desloratadine binds to this receptor with high affinity, preventing the natural mediator Histamine from activating the receptor. This action suppresses the signaling that leads to the physiological effects of Histamine release, such as the stimulation of sensory nerves and the increase in vascular permeability.

Modulation of the Inflammatory Pathway Cascade

Beyond H1-blockade, Desloratadine modulates the subsequent inflammatory cascade. This involves non-H1 inhibitory effects that limit the release of additional pro-inflammatory mediators, including specific cytokines (e.g., IL-4, IL-6) from cells like mast cells. This mechanism attenuates the overall biological response by reducing the recruitment and activation of inflammatory cells into affected tissues.

Negligible Central Nervous System (CNS) Activity

The molecule's chemical structure limits its ability to cross the blood-brain barrier (BBB). This means the mechanism of action is primarily restricted to peripheral H1-receptors, resulting in minimal interaction with the H1-receptors located in the CNS. This specificity defines the peripheral physiological action by resulting in negligible interaction with central pathways.

Dosage and Administration Information

Official Administration Guidelines for Elora

Proper use of Elora is defined by standardized guidelines detailing the specific methods, timing, and conditions of administration. The following instructions are based on the mechanics of use, without reference to therapeutic purpose or safety.

Administration Scope Official Labeled Instructions
Route of Administration Depending on the specific formulation, Elora is administered via the Oral, Transdermal, Intravenous Infusion, or Subcutaneous Injection route.
Dosing Schedule Dosing may be daily (e.g., 345 mg once daily), cyclic (e.g., once every three weeks), or involve a step-up schedule with initial lower doses followed by maintenance doses on specific days.
Timing in Relation to Meals Specific formulations require intake with food (e.g., to ensure proper absorption), while others may be taken regardless of mealtime.
Preparation Requirements Liquid concentrates for infusion must often be diluted with a specific solution (e.g., 5% Dextrose Injection) before administration.
Special Procedural Conditions Tablets must be swallowed whole without crushing, splitting, or chewing. Pre-treatment medications (e.g., corticosteroids) may be required before initial doses to reduce the risk of reaction.
Age/Population Rules Doses may require reduction or modification for patients with moderate to severe hepatic or renal impairment.

These administration guidelines establish the procedural structure for using the medicine. They define the precise dosage amount, the required timing, and specific handling instructions necessary to deliver the medicine according to established standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elora

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research examining the use of Elora (desloratadine) for seasonal and year-round respiratory allergies focuses primarily on Randomized Controlled Trials (RCTs). These short-term studies, which compare the compound against an inactive substance (placebo) or other active research compounds, were used in research exploring how symptoms change over time. The main outcomes monitored in these trials were patient-reported outcomes describing perceived discomfort related to sneezing, runny or itchy nose, and watery, itchy eyes.

Studies described patterns observed in the symptom scores over the short study period, which was typically between two and six weeks. Research also monitored the measured effect across the 24-hour dosing interval. The core evidence regarding measured outcomes is based on short-term study periods (e.g., 2–4 weeks). Comparative evidence is lacking for a definitive, consistent statement that the measured effect is different from all other second-generation antihistamines.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

The evidence base for Elora in conditions characterized by fluctuating manifestations like chronic idiopathic urticaria (hives) also relies heavily on Randomized Controlled Trials (RCTs). Research examined the severity of skin symptoms, focusing on outcomes linked to inflammatory or irritative states, such as the number and size of hives (wheals) and the intensity of itching (pruritus). The research also measured outcomes related to daily functioning or activity level, examining the interference of symptoms with sleep and routine life.

What is Still Uncertain About Elora

Research provides context about the known evidence, but also highlights what is still uncertain or where data remain insufficient. Long-term outcomes are not fully established because the follow-up durations were limited in most gold-standard RCTs. Therefore, research exploring the long-term patterns observed during continuous use lasting many months or years remains an area where data are still emerging, and certainty remains low. Subgroup findings are uncertain regarding the most suitable research approach for people whose symptoms are severely difficult to manage (refractory).

Key Studies & References

  1. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review
  2. Desloratadine Tablets Prescribing Information - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Elora (FAQ)

Q: What should I do if I miss a scheduled time for Elora?

A: Official patient instructions describe the procedure for a missed dose. Generally, the missed dose is to be taken as soon as it is remembered. If it is nearly time for the next dose, the missed dose is typically skipped, and the regular schedule is continued. Product information describes that a double amount is not to be used to make up for a missed amount.

Q: Can Elora cause weight gain or weight loss?

A: Official product information notes 'Weight increased' as an adverse reaction. However, the frequency of this occurrence is listed as 'Not known,' meaning there are not enough data from available studies to reliably estimate how often it occurs in the general population. Weight loss is not mentioned in the regulatory product labeling.

Q: How long does it typically take to start noticing a difference after taking Elora?

A: Pharmacokinetic studies indicate that the active substance, desloratadine, is absorbed well after use. It reaches its highest concentration in the bloodstream approximately three hours after it is taken. This measurement of plasma concentration provides context regarding the potential onset of the medicine's systemic presence.

Q: Will I have to take Elora forever?

A: The duration of use described in official product information depends on the condition it is being used for. For continuous or chronic conditions, the official product information indicates that treatment may be ongoing. For short-term issues, such as seasonal allergies, use may be limited only to the period of exposure.

Q: Can Elora be taken with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory studies have examined potential interactions between desloratadine and common pain relievers. According to this data, no clinically significant or notable interactions have been found with common pain relievers such as acetaminophen or ibuprofen.

Q: Does Elora interact with alcohol?

A: Regulatory documents state that desloratadine is not shown to increase the effects of alcohol or enhance performance impairment that may be caused by alcohol consumption. The official documentation for Elora notes that its use is not shown to increase the effects of alcohol.

Q: Is Elora safe to use during pregnancy?

A: Data regarding desloratadine use during pregnancy are insufficient for a definitive safety statement. Desloratadine has been observed in animal studies. For this reason, official regulatory information describes desloratadine's use during pregnancy as not advised.

Q: What does it mean if Elora has a 'Boxed Warning'?

A: A 'Boxed Warning' is the most serious type of safety alert required by the U.S. Food and Drug Administration (FDA) to be prominently displayed on a medication label. Its purpose is to call attention to a serious, possibly life-threatening, adverse reaction. Official prescribing information for Elora (desloratadine) does not currently contain an FDA Boxed Warning.

Q: Does Elora interact with common vitamins or supplements like Vitamin D?

A: Product information lists interactions with certain herbal products that can affect liver enzymes, such as St. John’s Wort. However, no clinically significant interactions have been found between desloratadine and common supplements like Vitamin D in official interaction studies.

Q: Can I take Elora if I have liver disease?

A: Official documentation notes that caution is a required consideration for patients with severe hepatic impairment (poor liver function). Pharmacokinetic recommendations describe that a modified or reduced dosing regimen may be applicable for adults with liver impairment.

Q: How long does Elora stay in the body after the last time it is used?

A: Pharmacokinetic data reported in regulatory documents indicates that the elimination half-life for desloratadine is approximately 27 hours in most individuals. This duration represents the time it takes for half of the compound to be eliminated from the body. This half-life may be longer in specific patient populations.

Q: Is a prescription needed for Elora?

A: The regulatory classification of desloratadine varies internationally. In certain countries or regions (such as the EU), specific strengths or formulations of the medicine may be available without a prescription. In other regions, a medical prescription is required for its supply.

Q: Is Elora approved in countries outside of the US?

A: Yes, the active substance, desloratadine, has been authorized for use by numerous major international health authorities. These include the European Medicines Agency (EMA) and government agencies in countries such as Canada and Japan.

Q: Can I use Elora if I am breastfeeding?

A: Official product information notes that desloratadine is known to be excreted into human breast milk. Regulatory guidance describes that use of this medicine is generally not advised for women who are breastfeeding.

Q: Does Elora affect blood pressure?

A: No direct effect on blood pressure is commonly reported for Elora (desloratadine) when used alone. However, its use has been studied in combination products with decongestants, and these combination products can be associated with an increase in blood pressure.

Q: Are there any specific lifestyle changes recommended while using Elora?

A: Official patient counseling information describes that activities requiring mental alertness, such as driving or operating complex machinery, should be avoided until an individual knows how the medicine affects them. This is due to the potential for adverse effects like drowsiness.

Q: What if Elora doesn't seem to be helping after a few weeks?

A: Regulatory guidance describes that a lack of symptom improvement or symptom worsening after a certain period is a signal to review the situation with a healthcare provider. The official advice notes this may indicate the medicine is not working as expected.

How should Elora be stored and disposed of?

How to Store and Dispose of Elora (Desloratadine)

The official storage requirements for Elora ensure its stability and effectiveness.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20 °C to 25 °C (68 °F to 77 °F). The product must be kept in its original container or blister packaging and protected from excessive moisture and light. It is essential to not freeze the medication, especially the liquid solution. As a mandatory safety rule, the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Elora should be disposed of using a medicine take-back program or by mixing it with an unappealing substance, placing it in a sealed bag, and discarding it with household trash. Do not dispose of the medicine by flushing it down the toilet or pouring it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Elora found in:

A-Z Index: